Form Type: 4

SEC EDGAR Link
Accession Number:0000899243-22-019682
Date:2022-05-24
Issuer: MERRIMACK PHARMACEUTICALS INC (MACK)
Original Submission Date:

Reporting Person:

CROCKER GARY L
C/O MERRIMACK PHARMACEUTICALS, INC.
ONE BROADWAY 14TH FLOOR CAMBRIDGE, MA 02142

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2022-05-24 P 2,323 a $5.09 125,872 indirect f2
COMMON STOCK 2022-05-25 P 132 a $5.13 126,004 indirect f2
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 the price reported in column 4 is a weighted average price. these shares were purchased in multiple transactions at prices ranging from $4.94 to $5.15, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this form 4.
f2 shares held by crocker family investments, llc, over which reporting person is the managing member.
f3 the price reported in column 4 is a weighted average price. these shares were purchased in multiple transactions at prices ranging from $5.13 to $5.15, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this form 4.

Elevate your investments